Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study.
C-telopeptide of collagen type 1 (CTX)
bone disease
bone metabolism
carfilzomib
multiple myeloma
nuclear factor kappa-B ligand (RANKL)
osteocalcin
procollagen type I N propeptide (PINP)
skeletal-related events
tartrate-resistant acid phosphatase-5b (TRACP-5B)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Mar 2021
12 Mar 2021
Historique:
received:
10
02
2021
revised:
07
03
2021
accepted:
11
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Carfilzomib with dexamethasone (Kd) is a well-established regimen for the treatment of relapsed/refractory multiple myeloma (RRMM). There is limited information for the effects of Kd on myeloma-related bone disease. This non-interventional study aimed to assess skeletal-related events (SREs) and bone metabolism in patients with RRMM receiving Kd, in the absence of any bone-targeted agent. Twenty-five patients were enrolled with a median of three prior lines of therapy; 72% of them had evidence of osteolytic bone disease at study entry. During Kd treatment, the rate of new SREs was 28%. Kd produced a clinically relevant (≥30%) decrease in C-telopeptide of collagen type-1 (
Identifiants
pubmed: 33809268
pii: cancers13061257
doi: 10.3390/cancers13061257
pmc: PMC7998249
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2013 Sep 16;8(9):e74191
pubmed: 24066119
Leukemia. 2014 Sep;28(9):1892-901
pubmed: 24518207
Leukemia. 2010 May;24(5):1043-9
pubmed: 20376081
Biomed Res Int. 2015;2015:172458
pubmed: 26579531
Health Technol Assess. 2014 Feb;18(11):1-180
pubmed: 24534414
Int J Mol Sci. 2018 Mar 26;19(4):
pubmed: 29587415
J Bone Oncol. 2018 Dec 26;14:100215
pubmed: 30666288
Stem Cell Res Ther. 2020 Nov 30;11(1):516
pubmed: 33256835
Ann Oncol. 2020 Dec;31(12):1650-1663
pubmed: 32801018
Blood. 2019 Apr 4;133(14):1534-1539
pubmed: 30760454
Leukemia. 2008 Dec;22(12):2247-56
pubmed: 18769451
Br J Haematol. 2003 Oct;123(1):106-9
pubmed: 14510950
Bone Rep. 2020 Apr 23;12:100272
pubmed: 32420416
Hemasphere. 2021 Feb 03;5(2):e528
pubmed: 33554050
Eur J Haematol. 2011 May;86(5):372-84
pubmed: 21366694
Leukemia. 2013 Feb;27(2):430-40
pubmed: 22763387
N Engl J Med. 2003 Dec 25;349(26):2483-94
pubmed: 14695408
Blood Cancer J. 2020 Mar 2;10(3):25
pubmed: 32123158
Adv Exp Med Biol. 2020;1231:13-21
pubmed: 32060842
Leukemia. 2010 Oct;24(10):1700-12
pubmed: 20811404
Int J Cancer. 2006 Oct 1;119(7):1728-31
pubmed: 16646053
Leukemia. 2007 Sep;21(9):1875-84
pubmed: 17611556
J Bone Miner Res. 2004 Mar;19(3):394-401
pubmed: 15040827
Expert Opin Ther Targets. 2009 Jul;13(7):839-48
pubmed: 19530987
Leuk Res. 2014 Aug;38(8):970-6
pubmed: 24939218
Leukemia. 2009 Nov;23(11):2177-81
pubmed: 19587705
Haematologica. 2011 Feb;96(2):333-6
pubmed: 20952514
Lancet Oncol. 2021 Mar;22(3):e119-e130
pubmed: 33545067
Int J Cancer. 2019 Jul 15;145(2):559-568
pubmed: 30650184
Cancer Treat Rev. 2012 Dec;38(8):968-80
pubmed: 22226939
Leukemia. 2011 Jul;25(7):1174-81
pubmed: 21403648
BMC Cancer. 2020 Mar 3;20(1):170
pubmed: 32126974
Blood. 2003 Aug 1;102(3):1064-9
pubmed: 12689925
Eur J Haematol. 2011 Jun;86(6):484-7
pubmed: 21477075
Lancet Oncol. 2018 Mar;19(3):370-381
pubmed: 29429912
Expert Rev Hematol. 2019 Aug;12(8):651-663
pubmed: 31268745
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Am J Hematol. 2019 Apr;94(4):400-407
pubmed: 30592079
Leukemia. 2014 Apr;28(4):928-34
pubmed: 24045498
Bone. 2016 May;86:131-8
pubmed: 26947893
Blood. 2013 Feb 7;121(6):893-7
pubmed: 23393020
Blood Cancer J. 2011 Jun;1(6):e27
pubmed: 22829171
Blood. 2017 Jun 29;129(26):3452-3464
pubmed: 28515094
Cancer. 2014 Mar 1;120(5):618-23
pubmed: 24249482
Int J Cancer. 2012 Sep 15;131(6):1466-71
pubmed: 22052418
Ann Oncol. 2012 Oct;23(10):2681-2686
pubmed: 22492699
Br J Haematol. 2006 Dec;135(5):688-92
pubmed: 17107351
Blood. 2007 Aug 15;110(4):1098-104
pubmed: 17494860
J Clin Invest. 2003 Jun;111(11):1771-82
pubmed: 12782679
Blood Cancer J. 2018 May 11;8(5):42
pubmed: 29748532
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5124-9
pubmed: 20194748
J Biol Chem. 2015 Jul 3;290(27):16918-28
pubmed: 25979341
Blood Cancer J. 2018 Jan 12;8(1):7
pubmed: 29330358
J Bone Miner Res. 2016 Jun;31(6):1225-34
pubmed: 26763740
Ann N Y Acad Sci. 2011 Nov;1237:19-23
pubmed: 22082361
Bone. 2017 Mar;96:29-37
pubmed: 27742498
Clin Lymphoma Myeloma Leuk. 2021 Jan 30;:
pubmed: 33714682